

ANA LYSEN

Molekularpathologie



VIOLLIER

Cancer Panels

Oncomine™ Comprehensive Assay v3 DNA, Thermo Fisher – 143 Gene

Hotspot-Mutationen

AKT1, AKT2, AKT3, ALK, AR, ARAF, AXL, BRAF, BTK, CBL, CCND1, CDK4, CDK6, CHEK2, CSF1R, CTNNB1, DDR2, EGFR, ERBB2 (=HER2), ERBB3, ERBB4, ERCC2, ESR1, EZH2, FGFR1, FGFR2, FGFR3, FGFR4, FLT3, FOXL2, GATA2, GNA11, GNAQ, GNAS, H3F3A, HNF1A, HRAS, IDH1, IDH2, JAK1, JAK2, JAK3, KDR, KIT, KNSTRN, KRAS, MAGOH, MAP2K1 (=MEK1), MAP2K2 (=MEK2), MAP2K4, MAPK1, MAX, MDM2, MDM4, MED12, MET, MTOR, MYC, MYCL, MYCN, MYD88, NFE2L2, NRAS, NTRK1, NTRK2, NTRK3, PDGFRA, PDGFRB, PIK3CA, PIK3CB, PPP2R1A, PTPN11, RAC1, RAF1, RET, RHEB, RHOA, ROS1, SF3B1, SMAD4, SMO, SPOP, SRC, STAT3, TERT, TOP1, U2AF1, XPO1

Komplettgensequenzierung

ARID1A, ATM, ATR, ATRX, BAP1, BRCA1, BRCA2, CDK12, CDKN1B, CDKN2A, CDKN2B, CHEK1, CREBBP, FANCA, FANCD2, FANCI, FBXW7, MLH1, MRE11, MSH2, MSH6, NBN, NF1, NF2, NOTCH1, NOTCH2, NOTCH3, PALB2, PIK3R1, PMS2, POLE, PTCH1, PTEN, RAD50, RAD51, RAD51B, RAD51C, RAD51D, RB1, RNF43, SETD2, SLX4, SMARCA4, SMARCB1, STK11, TP53, TSC1, TSC2

Kopienzahlveränderungen (CNVs)

AKT1, AKT2, AKT3, ALK, AR, AXL, BRAF, CCND1, CCND2, CCND3, CCNE1, CDK2, CDK4, CDK6, EGFR, ERBB2, ESR1, FGF19, FGF3, FGFR1, FGFR2, FGFR3, FGFR4, FLT3, IGF1R, KIT, KRAS, MDM2, MDM4, MET, MYC, MYCL, MYCN, NTRK1, NTRK2, NTRK3, PDGFRA, PDGFRB, PIK3CA, PIK3CB, PPARG, RICTOR, TERT

Oncomine™ Comprehensive Assay RNA, Thermo Fisher – 51 Fusionspartner

Genfusionen

AKT2, ALK, AR, AXL, BRAF, BRCA1, BRCA2, CDKN2A, EGFR, ERBB2, ERBB4, ERG, ESR1, ETV1, ETV4, ETV5, FGFR1, FGFR2, FGFR3, FGR, FLT3, JAK2, KRAS, MDM4, MET, MYB, MYBL1, NF1, NOTCH1, NOTCH4, NRG1, NTRK1, NTRK2, NTRK3, NUTM1, PDGFRA, PDGFRB, PIK3CA, PPARG, PRKACA, PRKACB, PTEN, RAD51B, RAF1, RB1, RELA, RET, ROS1, RSPO2, RSPO3, TERT

Oncomine™ Precision Assay DNA, Thermo Fisher – 46 Gene

Hotspot-Mutationen

AKT1, AKT2, AKT3, ALK, AR, ARAF, BRAF, CDK4, CDKN2A, CHEK2, CTNNB1, EGFR, ERBB2 (=HER2), ERBB3, ERBB4, ESR1, FGFR1, FGFR2, FGFR3, FGFR4, FLT3, GNA11, GNAQ, GNAS, HRAS, IDH1, IDH2, KIT, KRAS, MAP2K1 (=MEK1), MAP2K2 (=MEK2), MET, MTOR, NRAS, NTRK1, NTRK2, NTRK3, PDGFRA, PIK3CA, PTEN, RAF1, RET, ROS1, SMO, TP53

Kopienzahlveränderungen (CNVs)

ALK, AR, CD274, CDKN2A, EGFR, ERBB2, ERBB3, FGFR1, FGFR2, FGFR3, KRAS, MET, PIK3CA, PTEN

Oncomine™ Focus Assay RNA, Thermo Fisher – 23 Fusionspartner

Genfusionen

ABL1, ALK, AKT3, AXL, BRAF, EGFR, ERBB2, ERG, ETV1, ETV4, ETV5, FGFR1, FGFR2, FGFR3, MET, NTRK1, NTRK2, NTRK3, PDGFRA, PPARG, RAF1, RET, ROS1

NGS Kolorektalkarzinom

Hotspot-Mutationen

KRAS, NRAS, BRAF, PIK3CA

NGS Lungenkarzinom

Hotspot-Mutationen

EGFR, KRAS, BRAF, HER2, MET

Genfusionen

ALK1, ROS1, RET, NTRK1, NTRK2, NTRK3, MET Exon-14-Skipping

NGS Melanom

Hotspot-Mutationen

BRAF, KIT, NRAS, HRAS

NGS Gastrointestinaler Stromatumor (GIST)

Hotspot-Mutationen

KIT, PDGFRA

NGS Schilddrüsenkarzinom

Hotspot-Mutationen

AKT1, BRAF, CTNNB1, HRAS, KRAS, NRAS, PIK3CA, PTEN, RET, TERT, TP53

Genfusionen

RET, PPARG, NTRK1, NTRK2, NTRK3

NGS Endometriumkarzinom

Komplettgensequenzierung

POLE, TP53, MLH1, MSH2, MSH6, PMS2

NGS Urothelkarzinom

Hotspot-Mutationen und Fusionen

FGFR1, FGFR2, FGFR3, FGFR4

Komplettgensequenzierung

TP53

NGS Mammakarzinom

Komplettgensequenzierung

BRCA1, BRCA2, ATM, ATR, CDK12, CHEK1, CHEK2, FANCA, NBN, PALB2, RAD50, RAD51, RAD51B, RAD51C, RAD51D, PTEN

Hotspot-Mutationen

PIK3CA, AKT1, ESR1

NGS Ovarialkarzinom

TruSight Oncology 500 HRD powered by Myriad

Mutationen in BRCAness assoziierten Genen (inkl. BRCA1, BRCA2, PALB2) und Auswertung des Genomic Instability Score (GIS)

NGS Prostatakarzinom

TruSight Oncology 500 HRD powered by Myriad

Mutationen in BRCAness assoziierten Genen (inkl. BRCA1, BRCA2, ATM) und Auswertung des Genomic Instability Score (GIS)

Weitere Analysen:

BRCA1, BRCA2 Komplettgensequenzierung

Genomic Instability Score (GIS) TruSight Oncology 500 HRD powered by Myriad

Liquid Biopsy ESR1 OncomineTM Precision Assay GX

Mikrosatelliten-Instabilität (MSI) Fragmentlängenanalyse

MLH1-Promotormethylierung Fragmentlängenanalyse

Tumormutationslast (TMB) Illumina TruSight Oncology 500

Alle aufgeführten Analysen sind bei Viollier nach SN EN ISO 15189 akkreditiert.

Information

Dr. rer. nat. Henriette Kurth, Spezialistin für Labormedizin FAMH, Leiterin Molekularbiologie
Dr. med. Katharina Marston, FMH Pathologie, Molekularpathologie, Med. Leitung Molekularpathologie
Dr. med. Sophie Diebold Berger, FMH Pathologie, Zytopathologie, Leiterin Viollier Genève SA Pathologie
PD Dr. med. Andreas Zettl, FMH Pathologie, Kandidat Molekularpathologie, Leiter Pathologie

viollier.ch